The World Health Organization's emergency committee on the Ebola epidemic in the Democratic Republic of the Congo met for the second time on Tuesday, three months after the outbreak was declared a public health emergency of international concern. Director-General Tedros Adhanom Ghebreyesus did not soften his assessment when he opened the session. In remarks to the committee, he said the epidemic is far from being under control, that it had a big head start, and that responders are still playing catch-up.
The emergency designation, first issued in May, remains in place, and updated recommendations to affected and at-risk countries are expected to follow. The figures behind the committee's work moved again this week. Tedros told the meeting that almost 5,000 people have been infected and more than 2,300 have died across six provinces and 55 health zones. Case counts, funding figures, and official guidance may change as agencies release updated findings.
For readers in the United States, the practical stake is not the risk of infection at home, which federal officials continue to describe as very low. It is whether the response gets the money and field capacity it needs in the coming weeks, because the alternative is a longer emergency, a longer border restriction on travel from the region, and a longer wait for any medicine that works against this strain.
The Numbers Behind Tuesday's Meeting
Different agencies were reporting slightly different figures in the same week, and the gap is worth understanding rather than papering over. The World Health Organization counted 4,665 confirmed cases and 2,184 deaths in the DRC as of August 12, a crude case fatality ratio of 46.8 percent. Africa CDC reported more than 5,000 confirmed cases and more than 2,320 deaths as of August 17. Congolese government data cited by the United Nations put the totals at 4,945 confirmed cases and 2,325 deaths on the same date. The differences reflect reporting dates and data reconciliation, not a dispute about direction.
What the agencies agree on is the scale. This is now the largest Ebola outbreak ever documented in the DRC, surpassing the 2018 to 2020 epidemic, which recorded 3,317 confirmed cases. It is the deadliest in the country's history as well, passing the 2,299 deaths recorded in that earlier outbreak. Globally, it is second only to the West Africa epidemic of 2014 to 2016, which involved 28,616 cases and 11,310 deaths.
The pace is what alarms officials. During the week of August 3 to 9, the DRC recorded its highest weekly totals yet, with 579 confirmed cases and 304 deaths. Ituri province accounts for 85 percent of confirmed cases and 79 percent of deaths. Africa CDC put the current mortality rate at roughly one life every 30 minutes and said the epidemic's evolution has exceeded its gravest expectations.
A Containment Window That Runs on Money and Contact Tracing
WHO said earlier this month that it hopes to reverse the spread within three months by bringing transmission under control. Whether that happens depends heavily on financing. The joint Africa CDC and WHO continental preparedness and response plan seeks $518 million, and Tedros said just over half of that had been disbursed as of last week.
Two operational figures explain why officials are not more confident. As of August 12, teams were following up with 84.2 percent of listed contacts in the previous 24 hours, reaching 17,460 of 20,740 people. And Tedros told the emergency committee that what concerns him most is where people are dying: at home, in their communities, outside treatment centers, and outside known contact lists. Deaths occurring outside traced chains mean investigators are working with an incomplete picture of transmission.
Insecurity compounds the problem. WHO has recorded 12 attacks on health care since the emergency was declared, with more under verification. Those attacks curtail access for response teams, discourage patients from seeking care, and increase the risk of undetected transmission.
The Countermeasure Gap That Still Defines This Response
This outbreak is caused by the Bundibugyo virus, a species of Ebola for which no vaccine or specific treatment has been approved anywhere in the world. The two licensed Ebola vaccines, Ervebo and the Mvabea and Zabdeno regimen, target the Zaire species. A WHO technical advisory group has recommended that Ervebo be prioritized for inclusion in a randomized trial to test whether it offers cross-protection.
Research has moved faster than usual, though none of it produced a usable countermeasure this month. Tedros told the committee that two vaccines designed specifically against the Bundibugyo virus have entered human trials for the first time, and that a separate vaccine showing cross-protection in animal studies is being moved toward a phase three trial. The WHO-sponsored PARTNERS treatment trial, which is evaluating remdesivir and the antibody therapy MBP134, began enrolling on July 2 and has now enrolled 100 patients across three clinical management facilities in Ituri.
That gap is why the American response has leaned so heavily on the border. The Centers for Disease Control and Prevention reports no Ebola cases in the United States connected to this outbreak and assesses the likelihood of spread here as very low. Under an order renewed on August 12, travelers who have been in the DRC within 21 days of their flight, including Americans, will not be allowed to board commercial flights bound for the United States. Travelers who have been in Uganda or South Sudan but not the DRC must enter through designated airports for enhanced screening. WHO, for its part, continues to advise against restricting travel to or trade with affected countries.
The People Carrying the Heaviest Burden Right Now
Risk in this epidemic is concentrated, not general. Households in Ituri, North Kivu, South Kivu, Haut-Uele, Tshopo, and Bas-Uele provinces face direct exposure, particularly families caring for a sick relative at home or handling bodies after death, which WHO identifies as the settings where transmission is most amplified.
Health and care workers are a second group. As of August 9, WHO had counted at least 155 confirmed infections among them, including 45 deaths and 68 recoveries. The agency attributes these to occupational exposure and to the difficulty of applying infection control outside designated Ebola treatment centers, where protocols and supplies are more established.
Americans with the greatest practical exposure are aid workers, missionaries, researchers and people with family in the affected provinces. Anyone in that category should confirm medical evacuation coverage before travel, plan for a 21-day gap outside the DRC before returning to the United States, monitor for symptoms for 21 days after leaving the region, and call a clinician or local health department before arriving in person so the facility can prepare. Travelers with no connection to the region do not need to change their routine plans.
What remains unresolved is substantial. The true number of infections is unknown; no therapy has yet been shown to work against this species; and whether the required funding will materialize remains uncertain. MedicalDaily previously reported that the outbreak had become the deadliest recorded there, and the committee's updated recommendations are expected shortly.
Key Questions Answered
What happened this week? WHO's emergency committee held its second meeting on the outbreak. The public health emergency of international concern declared in May remains in place, and updated temporary recommendations to states are expected to follow.
How many people have been infected? Reported totals differ by source and date. WHO counted 4,665 confirmed cases and 2,184 deaths as of August 12. Africa CDC reported more than 5,000 cases and more than 2,320 deaths as of August 17.
Is the outbreak still growing? Yes. WHO describes it as being in a phase of intense transmission, and the week of August 3 to 9 produced the highest weekly case and death counts recorded so far.
Can it still be contained? WHO has said it hopes to reverse the spread within three months. The continental response plan seeks $518 million, and only about half had been disbursed as of last week.
Is there a vaccine? Not an approved one for this strain. Bundibugyo virus has no licensed vaccine or specific treatment. Two candidate vaccines have entered human trials, and a trial of the licensed Ervebo vaccine has been recommended to test for cross-protection.
What is the risk inside the United States? The CDC assesses the likelihood of spread here as very low. No cases linked to this outbreak have been confirmed on U.S. soil.
Can Americans fly home directly from the DRC? No. Travelers who have been in the DRC within 21 days of their flight, including U.S. citizens, cannot board commercial flights to the United States and should plan to remain outside the country for 21 days.
